Table III.
The severity of COVID-19 and the clinical features of its systemic symptoms
| Analyzed parameters | Values |
|---|---|
| Patients with at least 1 comorbidity, n (%)∗ | 86 (43) |
| Median duration of systemic symptoms, days (IQR)† | 23 (12-31) |
| Systemic symptoms, n (%) | |
| Fever | 146 (73) |
| Cough | 108 (54) |
| Pneumonia | 106 (53) |
| Dyspnea | 77 (38.5) |
| Gastrointestinal symptoms | 46 (23) |
| Hypogeusia/hyposmia | 44 (22) |
| Thromboembolic complications | 11 (5.5) |
| Death | 7 (3.5) |
| Disease severity, n (%) | |
| Asymptomatic | 31 (15.5) |
| Mild | 51 (25.5) |
| Moderate | 95 (47.5) |
| Severe | 23 (11.5) |
| Diagnosis of COVID-19, n (%) | |
| Suspected | 73 (36.5) |
| Laboratory confirmed | 127 (63.5) |
| Duration of systemic symptoms, days, median (IQR) | |
| Urticarial rash‡ | 21 (11-39.5) |
| Confluent erythematous/maculopapular/morbilliform rash§ | 28 (19-38) |
| Papulovesicular exanthemaǁ | 19 (12-28.5) |
| Chilblain-like acral pattern¶ | 13 (7-21) |
| Livedo reticularis/racemosa-like pattern# | 26 (11.75-48.25) |
| Purpuric vasculitic pattern∗∗ | 22 (8.75-33.5) |
Data were available for the following numbers of patients: 195,∗ 124,† 17,‡ 39,§ 13,ǁ 21,¶ 6,# and 12.∗∗